In contrast with the previous thought of KRAS mutant independency from upstream RTK, recent data demonstrate that the genetic abrogation of EGFR resulted in impaired tumor growth of KRAS mutant NSCLC models. The gene discussed is EGFR; the disease is neoplasm.